• Regimens, Medicines, and Physiotherapy

  Orkambi Approved in Europe for Young Children with Cystic Fibrosis

  Posted by cystic-fibrosis-news-moderator on January 30, 2019 at 6:56 pm

  The European Commission has approved Orkambi’s label extension to include cystic fibrosis patients ages 2-5 with two copies of the 508del mutation. Click here to learn more.

  Do you agree with this decision? Will it impact you or anyone you know?

  cystic-fibrosis-news-moderator replied 5 years, 2 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply